Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1208-1218

  Bobola, Michael S ^a   Kolstoe, Douglas D ^a   Blank, A ^a,b   Silber, John R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; 6 O METHYLGUANINE; DNA GLYCOSYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GAMMA IRRADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GAMMA RAYS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MAXIMUM TOLERATED DOSE; RADIATION TOLERANCE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 77952207481     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0010     Document Type: Article

References (45)

1. Norden AD, Wen PY. Glioma therapy in adults. Neurologist 2006;12: 279-292
2. Mason WP, Cairncross JG. Drug Insight: temozolomide as a treatment for malignant glioma - impact of a recent trial. Nat Clin Pract Neurol 2005;1:88-95.
3. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466
4. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma-look to the future. Nat Clin Pract Oncol 2008; 5:476-486
5. Payne MJ, Pratap SE, Middleton MR. Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol 2005;53:241-252
6. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997;23: 35-61. (Pubitemid 27273454)
7. Marchesi F, Turriziani M, Tortorelli G, Avisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 2007;56:275-287 (Pubitemid 47488901)
8. 6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-4199
9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354
10. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007;6: 1079-1099
11. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000;47: 779-784
12. Hermisson M, Klumpp A, Wick W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-776
13. Chakravarti A, Erkkinen MG, Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006;12:4738-4746 (Pubitemid 44297828)
14. van Nifterik KA, van den Berg J, Stalpers LJ, et al. Differential radio-sensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007; 69:1246-1253 (Pubitemid 47625874)
15. Kil WJ, Cerna D, Burgan WE, et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008;14:931-938
16. Wyatt MD, Pittman DL. Methylating agents and DNA repair responses: methylated bases and sources of strand breaks. Chem Res Toxicol 2006;19:1580-1594
17. Bobola MS, Varadarajan S, Smith NW, et al. Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin. Clin Cancer Res 2007;13:612-620 (Pubitemid 46225368)
18. Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 1996;2:735-741 (Pubitemid 26135342)
19. 6-methylguanine: implications for WRN function. DNA Repair (Amst) 2004;3:629-638
20. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-20312
21. Bonner WM, Redon CE, Dickey JS, et al. γ-H2AX and cancer. Nat Rev Cancer 2008;8:957-967
22. Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003;61:203-207
23. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-1030
24. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-3736
25. 6-methylguanine: T, G:U mispairs in DNA by human cell extracts. Biochemistry 2002;41:9248-9255
26. 6-methylguanine:thymine mispairs in DNA by extracts of human cells. Biochemistry 1992;31:7998-8008.
27. Fronza G, Gold B. The biological effects of N3-methyladenine. J Cell Biochem 2004;91:250-257
28. Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet 2006;40:363-383 (Pubitemid 44956790)
29. O'Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet 2006;7:45-54.
30. 6-methylguanine lesions in human nuclear extracts. J Biol Chem 2006;281:22674-22683
31. Plosky BS, Frank EG, Berry DA, Vennall GP, McDonald JP, Woodgate R. Eukaryotic Y-family polymerases bypass a 3-methyl-2′-deoxyadenosine analog in vitro and methyl methanesulfonate-induced DNA damage in vivo. Nucleic Acids Res 2008;36: 2152-2162
32. Engelward BP, Allan JM, Dreslin AJ, et al. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J Biol Chem 1998;273:5412-5418
33. Merrick CJ, Jackson D, Diffley JF. Visualization of altered replication dynamics after DNA damage in human cells. J Biol Chem 2004;279: 20067-20075
34. Sidorova JM, Li N, Folch A, Monnat RJ Jr. The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest. Cell Cycle 2008;7:796-807.
35. Branzei D, Foiani M. Interplay of replication checkpoints and repair proteins at stalled replication forks. DNA Repair (Amst) 2007; 6:994-1003.
36. Jansen JG, Fousteri MI, de Wind N. Send in the clamps: control of DNA translesion synthesis in eukaryotes. Mol Cell 2007;28: 522-529
37. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 2009;5:e1000324.
38. Ward JF. Radiation mutagenesis: the initial DNA lesions responsible. Radiat Res 1995;142:362-368
39. Cahill DP, Levine KK, Betensky RA, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007;13:2038-2045
40. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009;15:4622-4629
41. Chang DJ, Cimprich KA. DNA damage tolerance: when it's OK to make mistakes. Nat Chem Biol 2009;5:82-90.
42. Sidorova JM. Roles of the Werner syndrome RecQ helicase in DNA replication. DNA Repair (Amst) 2008;7:1776-1786
43. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005;31:603-617
44. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4:1364-1368
45. Russo AL, Kwon HC, Burgan WE, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009;15:607-612